The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Very early molecular marker of tumor response to PD-1 inhibition in plasma of patients with advanced non-small cell lung cancer (NSCLC).
 
Thijo Jeroen Nicolaas Hiltermann
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst)
 
A Miedema
No Relationships to Disclose
 
Lucie Hijmering-Kappelle
No Relationships to Disclose
 
Harry J.M. Groen
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Lilly (Inst); Roche (Inst)
 
Ed Schuuring
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Biocartis (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Speakers' Bureau - Biocartis; Illumina; Novartis
Research Funding - Boehringer Ingelheim (Inst); Roche (Inst)